Leukemia & Lymphoma最新文献

{"title":"The roles of RUNX1 in megakaryocyte differentiation in myeloid leukemia.","authors":"Yan Xie, Ianian Ng, Yuankai Liu, Haitao Wang, Qiong Yang","doi":"10.1080/10428194.2026.2718439","DOIUrl":"https://doi.org/10.1080/10428194.2026.2718439","url":null,"abstract":"<p><p>Runt-related transcription factor 1/acute myeloid leukemia 1 (RUNX1/AML1) is essential for the generation of myeloid progenitor cells and differentiation of megakaryocytes (MKs). During megakaryocyte differentiation and maturation, RUNX1 forms transcriptional complexes with transcription factors such as GATA-1, Ets-1, Fli-1, and NF-E2 to promote platelet production. Disruption of RUNX1 is implicated in hematopoietic neoplasms like familial platelet disorder (FPD/AML), myelodysplastic syndrome (MDS) and acute myeloid leukemia. Here, we review the transcriptional regulation of RUNX1 in megakaryocyte differentiation of normal individuals and myeloid leukemia patients. We also summarize post-translational modifications (PTMs) of RUNX1 and discuss their potential implications for novel RUNX1-directed leukemia therapies.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.","authors":"Alyssa Kassouf, Rina Li Welkie, Yazeed Sawalha, Audrey Sigmund, Timothy Voorhees, Yun Choi, Robert Baiocchi, Jordan Lundberg, Tracy Wiczer, Tyler Everhardt, Rebecca Evers, Lindsay Rosen, Beth Christian, Kami Maddocks, David A Bond","doi":"10.1080/10428194.2026.2718433","DOIUrl":"https://doi.org/10.1080/10428194.2026.2718433","url":null,"abstract":"<p><p>Chemotherapy-induced nausea and vomiting (CINV) is an important side effect of the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and BV-AVD (brentuximab, vedotin, doxorubicin, vinblastine, dacarbazine) regimens for classical Hodgkin lymphoma (cHL). The same anti-emetic prophylaxis strategies are commonly used for both; however, the comparative incidence of CINV between regimens is not well described. We conducted a retrospective cohort study of cHL patients treated with ABVD (n = 87) or BV-AVD (n = 57) given standard anti-emetic prophylaxis with dexamethasone and palonosetron or ondansetron. Clinically significant nausea was more frequent in the BV-AVD cohort (44% vs 20%, <i>p</i> < 0.01), alongside higher rates of hospitalization or emergency department visits for CINV (18% vs 2.3%, <i>p</i> < 0.01) and significant weight loss (40% vs 7.0%, <i>p</i> < 0.0001). Multivariable analysis showed BV-AVD treatment was the only variable independently associated with clinically significant CINV. These findings suggest BV-AVD is more emetogenic than ABVD and that two drug anti-emetic prophylaxis is suboptimal for AVD-based regimens.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors of 10-year survival in patients with myeloma after autologous stem cell transplantation: a multicenter retrospective analysis.","authors":"Kazuhito Suzuki, Ichiro Hanamura, Hiroyuki Takamatsu, Koji Kawamura, Emiko Sakaida, Masaki Ri, Keisuke Kataoka, Akira Hangaishi, Kazutaka Sunami, Akio Saito, Yuta Katayama, Noriko Doki, Hideyuki Nakazawa, Shinsuke Iida, Shingo Kurahashi, Shuichi Ota, Hitoji Uchiyama, Masashi Sawa, Yoshinobu Kanda, Junya Kanda, Yoshiko Atsuta, Shingo Yano, Nobuhiro Tsukada","doi":"10.1080/10428194.2026.2716453","DOIUrl":"https://doi.org/10.1080/10428194.2026.2716453","url":null,"abstract":"<p><p>Prognostic factors for long-term survival (LTS), defined as overall survival (OS) of ≥10 years, remain uncertain among patients with myeloma who undergo autologous stem cell transplantation (ASCT). We retrospectively analyzed 3650 patients with myeloma who underwent ASCT between 1994 and 2013 using the Japanese Society of Transplantation and Cellular Therapy registry. The proportion of long-term survivors was 28.7%. In logistic regression analyses, IgG-type, absence of high-risk cytogenetic abnormality (HRCA), International Staging System (ISS) I/II, and post-transplantation therapy were associated with LTS. Cox regression analysis revealed that kappa light chain type and post-transplantation therapy predicted better OS, whereas PS 2-4, HRCA, melphalan dose under 200 mg/m², and ISS III predicted a shorter OS. We classified patients into three groups on the six significant factors; the estimated 10-year OS among the favorable group was 60.9%. ISS, HRCA, M-protein subtype, melphalan dose, achieving CR, and post-transplantation therapy were associated with LTS after ASCT.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.","authors":"Jenna Ciervo, Anthony J Perissinotti, Adam J DiPippo, Kayleigh Marx, Lydia L Benitez, Caitlin Rausch, Kaitlyn Buhlinger, Benyam Muluneh, Hailey Hirata, Jeffrey Baron, Emma Uchida, Ashley Soule, Shawn P Griffin, Benjamin J Lee, Mimi Lo, Thu Doan, Janine Martino, Ila Saunders, Bernard L Marini","doi":"10.1080/10428194.2026.2711164","DOIUrl":"https://doi.org/10.1080/10428194.2026.2711164","url":null,"abstract":"<p><p>Patients with accelerated-phase/blast-phase myeloproliferative neoplasms (AP/BP-MPN) experience poor clinical outcomes. A multicenter, retrospective cohort study was conducted to assess outcomes of patients with AP/BP-MPN treated with hypomethylating agent (HMA) regimens. Of 188 patients included, 94 patients received HMA +/- JAK inhibitor and 56 patients received HMA + venetoclax (HMA+ven) +/- JAK inhibitor. The primary endpoint of overall survival (OS) was 9.2 months in both groups (log-rank <i>p</i> = 0.569). The rates of CR/CRi and CR/CRi/MLFS were higher with HMA+ven (36% vs. 11%, <i>p</i> = 0.0002 and 52% vs. 16%, <i>p</i> < 0.0001), but the rate of allogeneic hematopoietic cell transplant (alloHCT) was not different (HMA vs. HMA+ven, 14% vs. 18%, <i>p</i> = 0.51). Multivariate cox regression identified age and receipt of an alloHCT as significant predictors of survival. This large, multicenter, real-world analysis demonstrated the addition of venetoclax to HMA therapy in patients with AP/BP-MPN improved response rates but did not translate into an improvement in OS.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.","authors":"Marcel von Lucadou, Lea-Corinna Burbaum, Melanie Märklin, Jonas S Heitmann, Susanne Jung","doi":"10.1080/10428194.2026.2707891","DOIUrl":"https://doi.org/10.1080/10428194.2026.2707891","url":null,"abstract":"<p><p>Soluble immune mediators, such as checkpoint and cytokine receptors and their ligands, are emerging as biomarkers and potential therapeutic targets in hematologic malignancies. We assessed pretreatment levels of soluble PD-L1 (sPD-L1) as a prognostic biomarker in a retrospective single-center cohort of 54 newly diagnosed acute myeloid leukemia (AML) patients. Higher sPD-L1 levels were significantly associated with a greater disease burden and with patients undergoing allogeneic transplantation. Interpretation of longitudinal sPD-L1 data suggests that marked declines may reflect treatment response, whereas persistently high levels may indicate ongoing disease activity. In non-transplanted patients, high sPD-L1 levels were independently associated with inferior overall survival. These results indicate that sPD-L1 may inherently reflect high-risk characteristics that could potentially help guide treatment decisions.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study.","authors":"Bradley Uyemura, Fauzia Hollnagel, Aric Hall, Mathew Brunner, Zhubin Gahvari, Ryan J Mattison, Hongtao Liu, Michael J Fallon, Kalyan V Nadiminti","doi":"10.1080/10428194.2026.2711591","DOIUrl":"https://doi.org/10.1080/10428194.2026.2711591","url":null,"abstract":"<p><p>Biological markers such as disease risk and mutation profile can predict survival outcomes of acute myeloid leukemia (AML) treated with first-line venetoclax (Ven) in combination with a hypomethylating agent. However, the impact of socioeconomic factors with this regimen is unclear. Using a widely validated metric of disadvantage, Area Deprivation Index (ADI), we investigated the influence of socioeconomic disparity on overall survival (OS) in seventy-nine newly diagnosed patients with AML who received Ven-based therapy at the University of Wisconsin. Median OS was 6.77 months (IQR 2.52-11.57) with a cumulative mortality rate of 75.9%. While previous reports demonstrated worse outcomes in disadvantaged patients treated with intensive therapy, we observed no statistically significant difference between State/National ADI and OS (<i>p</i> = 0.697 and <i>p</i> = 0.582 respectively) in our Ven cohort.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies.","authors":"Danny Trotier, Manlu Liu, Arun Augustine, Kiruba Vembu, Meaghan Trainor, Priyanka Pophali","doi":"10.1080/10428194.2026.2715204","DOIUrl":"https://doi.org/10.1080/10428194.2026.2715204","url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell therapy (CART) has changed treatment for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but most patients still die of their disease and may benefit from palliative care (PC) or hospice services. Whether CART availability has affected PC or hospice referral patterns and end-of-life outcomes remains unclear. We conducted a single-center retrospective study for deceased patients with r/r DLBCL to evaluate PC and hospice utilization before and after CART introduction (87 pre-CART, 95 post-CART). PC referral rates were similar between eras (57.5% vs 70.5%, <i>p</i> = 0.39), as were hospice referrals (79.3% vs 83.2%, <i>p</i> = 0.78). However, patients in the post-CART era had shorter time from last treatment to death (95 vs 51 days, <i>p</i> = 0.001), higher hospitalization rates in the last 30 days of life (57.5% vs 72.6%, <i>p</i> = 0.03), and more in-hospital deaths (19.5% vs 33.7%, <i>p</i> = 0.045). Overall, 20-30% of patients were never referred to PC or hospice.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of O-GlcNAc glycosylated modified transferase on prognosis of diffuse large B-cell lymphoma and analysis of downstream targets.","authors":"Chengji Wang, Yuanzheng Liang, Xindi Liu, Lijie Zeng, Liang Wang","doi":"10.1080/10428194.2026.2712107","DOIUrl":"10.1080/10428194.2026.2712107","url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically heterogeneous malignancy, but the prognostic and biological significance of O-linked β-N-acetylglucosamine (O-GlcNAc) modification remains incompletely understood. We analyzed three microarray-based DLBCL cohorts obtained from the Gene Expression Omnibus (GSE87371, GSE117556, and GSE181063; total n = 2,090). Consensus clustering was used to characterize the expression patterns of glycosylation-related genes. The associations of these expression patterns and O-GlcNAc transferase (OGT) expression with overall survival were evaluated using Kaplan-Meier analysis and Cox regression. Differential expression, pathway enrichment, single-sample gene set enrichment, and correlation analyses were performed to characterize biological features associated with OGT expression. We also used OCI-LY3 and SU-DHL-4 cell lines to investigate the effects of OGT overexpression, shRNA-mediated knockdown, and pharmacological inhibition on cell proliferation and apoptosis. Co-immunoprecipitation and immunoblotting were performed to assess protein O-GlcNAcylation and phosphorylation, together with selected signaling proteins, anti-apoptotic factors, and epigenetic regulators. In result, Glycosylation-related genes displayed heterogeneous expression patterns across DLBCL samples that were associated with survival, with OGT emerging as a key prognostic candidate. High OGT expression was associated with shorter survival in all three cohorts, and patients with OGT overexpression and high International Prognostic Index scores had particularly poor outcomes. Increased levels of OGT expression co-varied with PI3K-AKT-MTOR signaling, MYC target signaling, and selected anti-apoptotic and epigenetic features. In both cell lines, OGT overexpression promoted proliferation and was accompanied by increased O-GlcNAcylation and activation-associated phosphorylation of PI3K, AKT, and Myc, together with increased protein levels of Bcl-2, Mcl-1, EZH2, and KMT2D. OGT knockdown or pharmacological inhibition produced opposite changes and increased apoptosis. These findings indicate that elevated OGT expression is associated with unfavorable survival and adverse signaling features in DLBCL. Further studies are required to establish the direct causal relationships and therapeutic significance of OGT-associated O-GlcNAcylation.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-26"},"PeriodicalIF":2.1,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148726507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additional myelodysplasia-related gene mutations alter clinical presentation and worsen prognosis in patients with <i>SRSF</i>/<i>TET2</i> co-mutated myeloid neoplasms.","authors":"Michael Martin, Samuel G Cockey, Veena Jajoo, Mac Shebes, Hailing Zhang, Le Wang, Lynn Moscinski, Julie Li, Emily Coughlin, Rahul Mhaskar, Jinming Song","doi":"10.1080/10428194.2026.2714598","DOIUrl":"10.1080/10428194.2026.2714598","url":null,"abstract":"<p><p><i>SRSF2/TET2</i> is a common co-mutation characterized by monocytosis across many myeloid neoplasms, including CMML. Myelodysplasia-related gene (MRG) mutations, including <i>SRSF2</i>, <i>SF3B1</i>, <i>U2AF1</i>, <i>ZRSR2</i>, <i>ASXL1</i>, <i>EZH2</i>, <i>BCOR</i>, and <i>STAG2</i>, are key contributors to leukemic transformation, though their interactions with other mutations are understudied. In this retrospective cohort study, we examined the clinical and prognostic impact of additional mutated MRGs in 412 patients with <i>SRSF2</i>/<i>TET2</i> co-mutated neoplasms, identified from the Moffitt Next Gen Sequencing Database. The majority of patients (55%) had at least one additional MRG mutation, which was associated with decreased monocytosis, increased anemia, and poorer overall survival (10.941 vs. 23.787 months, <i>p</i> < 0.001). <i>ASXL1</i> was the most common MRG mutation and independently predicted worse survival. Patients with additional MRGs were more likely to have AML arising from CMML (12.3% vs 5.9%, <i>p</i> = 0.029). These findings may be used in future clinical practice to provide better prognosis and treatment stratification.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148722929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.","authors":"Yotam Bronstein, Lior Rokach, Yair Herishanu, Ronen Arbel, Talish Razi, Noy Nachmias","doi":"10.1080/10428194.2026.2711592","DOIUrl":"https://doi.org/10.1080/10428194.2026.2711592","url":null,"abstract":"<p><p>Liver biochemical abnormalities are relatively common at chronic lymphocytic leukemia (CLL) diagnosis, but their prognostic significance is unclear. We conducted a nationwide real-world study of 3448 adults with newly diagnosed CLL in Clalit Health Services, Israel, with liver biochemistry assessed within ±3 months of diagnosis and no documented preexisting liver disease. Cholestatic elevation was defined as elevated alkaline phosphatase and/or gamma-glutamyl transferase; hepatocellular elevation as elevated alanine and/or aspartate aminotransferase. Median follow-up was 74.9 months. Cholestatic and hepatocellular elevations were present in 16.4% and 6.0% of patients, respectively. In multivariable Cox models, cholestatic elevation was independently associated with inferior overall survival (hazard ratio (HR), 1.21; 95% CI, 1.05-1.39; <i>p</i> = 0.008), whereas hepatocellular elevation did not. Neither pattern was independently associated with time to first treatment. Cholestatic elevation was also associated with increased infection-related hospitalization rates and hospitalized days, identifying a clinically vulnerable subgroup at CLL diagnosis.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2026-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}